Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Liza Avruch"'
Autor:
Anthony R. Mato, Alexey V. Danilov, Neil E. Kay, John M. Pagel, Robyn Brumble, John C. Byrd, Liza Avruch, Chaitra S. Ujjani, Alan P Skarbnik, Neil Bailey, Nicole Lamanna, Richard R. Furman, Nitin Jain, Chris Stewart, Brian Koffman, Matthew S. Davids
Publikováno v:
Blood. 138:1927-1927
Introduction: The management of CLL patients historically utilized FD chemoimmunotherapy (CIT), including fludarabine, cyclophosphamide and rituximab (FCR), or bendamustine and rituximab (BR). That changed with the introduction of Bruton Tyrosine Kin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bde3b4daeccf2292ecccef7658d775d9
https://doi.org/10.1182/blood-2021-145046
https://doi.org/10.1182/blood-2021-145046
Autor:
Byung Park, Andy Kaempf, Babak Movassaghi, Brian Koffman, Christopher Lee, Alan P Skarbnik, Matthew S. Davids, John M. Pagel, Liza Avruch, Alexey V. Danilov, John C. Byrd
Publikováno v:
Blood. 134:4716-4716
Introduction: It has long been recognized that expert care can improve outcomes for CLL patients (pts). Moreover, CLL treatment has rapidly changed over the past several years, making it challenging for healthcare providers (HCP) to keep pace with ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::08e63d6ff979107d6db428f75c7ec555
https://doi.org/10.1182/blood-2019-123579
https://doi.org/10.1182/blood-2019-123579